Posted from: Thursday, July 31, 2014 - 01:15 PM - Present

New Drug, Zydelig, Approved to Treat Blood Cancer

July 23, 2014 – Gilead’s Zydelig (idelalisib) was approved by the Food and Drug Administration (FDA) for the treatment of three types of blood cancer. 

Zydelig was approved to treat relapsed chronic lymphocytic leukemia (CLL), in combination with Rituxan (rituximab) and the FDA also granted accelerated approval to Zydelig to treat relapsed follicular B-cell non-Hodgkin lymphoma (FL) and relapsed small lymphocytic lymphoma (SLL), another type of non-Hodgkin lymphoma. Zydelig is intended to be used in patients who have received at least two prior systemic therapies.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.


Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Friday, October 11, 2019 - 07:31 PM.